LAPTM4B-35 protein as a potential therapeutic target in gastric cancer

Abstract

The objective of this study is to investigate lysosome-associated protein transmembrane 4b-35 (LAPTM4B-35) protein expression in gastric cancer and its clinical implications. LAPTM4B-35 protein expression in 652 gastric cancer specimens and matched adjacent non-cancerous tissues was evaluated by immunohistochemical staining. Subsequently, the relationship between LAPTM4B-35 protein expression, clinical pathological parameters, and prognosis of gastric cancer was determined. LAPTM4B-35 protein expression was significantly higher in gastric cancer tissue compared to adjacent non-cancerous tissues (P = 0.001). In total, 417 (63.96 %) of the 652 gastric cancer cases demonstrated high LAPTM4B-35 protein expression. Multiple regression analysis was performed to identify the factors related to lymph node metastasis. As a result, age, tumor number, primary tumor category, histological type, histological growth pattern, and LAPTM4B-35 protein expression were found to be significantly related to lymph node metastasis (P = 0.010, 0.001, 0.032, 0.001, 0.001, and 0.001, respectively). Survival analysis identified that LAPTM4B-35 protein expression was also an independent prognostic factor (P = 0.001). LAPTM4B-35 was highly expressed in gastric cancer and may be a potential target for the management of gastric cancer.

Possible Prognostic Potential of RANKL and OPG in Metastatic Breast Cancer Egyptian Females

“…A similar result was detected by Xiao et al, (2013), who reported that LAPTM4B was activated and overexpressed in serum of BC patients. Moreover, other studies have demonstrated that LAPTM4B has been upregulated in many human cancers, such as lung cancer (Tang et al, 2014), gastric cancer (Zhang et al 2014), and prostate cancer (Zhang et al, 2015), and is known to have a role as a dynamic cancer-associated biomarker that is involved in several biological processes (Kasper et al, 2005). We observed significant increases in both RANKL and OPG serum levels in the MBC group compared with the control and NMBC groups.…”

The Transcription Factor AP4 Promotes Oncogenic Phenotypes and Cisplatin Resistance by Regulating LAPTM4B Expression

“…LAPTM4B, an oncogene, is highly expressed in many solid tumors and inversely associated with overall survival and disease-free survival of patients with breast cancer [31], gastric cancer [32], gallbladder cancer [33], HCC [34], ovarian cancer [35] and cervical cancer [36]. Moreover, the polymorphism region in the 5ʹ-UTR of …”

“…It could promote the proliferation of tumor cells, boost invasion and metastasis, resist apoptosis, initiate autophagy and assist drug resistance [4]. In addition, overexpression of LAPTM4B was significantly correlated with poor prognosis in breast cancer [5], gallbladder cancer [6,7], ovarian cancer [8], HCC [9][10][11], gastric cancer [12] and cervical cancer [13] LAPTM4B gene has two alleles named LAPTM4B*1 and LAPTM4B*2 (GenBank numbers AY219176 and AY219177, respectively). Allele *1 contains only one copy of a 19-bp sequence at the 5'UTR in the first exon, whereas the sequence in allele *2 is duplicated and tandemly repeated [14].…”

Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients

“…Previous studies showed that LAPTM4B-35 activity was elevated in various malignant tumors, which was associated with poor prognosis [4–6]. Moreover, it was indicated that LAPTM4B could increase the proliferation and metastasis of tumor cells, reduce apoptosis, and assist drug resistance, which involved in activated PI3K/AKT and Ras-MAPK signaling pathways [7].…”